How to Appeal a Wegovy Insurance Denial: Coverage, Exceptions and Next Steps

By Your Health Magazine Contributor

Your Health Magazine Contributor

. https://YourHealthMagazine.net

More Weight Control, Nutrition & Exercise Articles

How to Appeal a Wegovy Insurance Denial: Coverage, Exceptions and Next Steps

Insurance denials often end treatment before it starts. A 2026 JAMA study found that 48.4% of people whose first attempt to fill a single-source brand-name drug was rejected received neither that drug nor another medication in the same class within 90 days; weight-management incretin drugs had the highest initial rejection rate in the study. Separately, earlier HealthCare.gov claims data found that fewer than 1% of denied claims were appealed. The studies measure different things, but together they illustrate how often coverage barriers go unchallenged.

For Wegovy, walking away after a denial may be premature. A KFF analysis of 2024 federally facilitated ACA Marketplace formularies found Wegovy on only about 1% of plans, although coverage varies and formularies can change. Wegovy also now has FDA-approved indications beyond weight management, which may matter in some appeals depending on the patient’s diagnosis and plan terms.

If your health plan denies coverage, the denial notice should explain why and describe the appeal rights available under the plan. Appeal rights, review levels, and deadlines can vary by coverage type, so the denial notice and plan documents are the best place to start.

Reading the Denial

The letter from your insurer must state why coverage was refused, what your appeal rights are, and how long you have to file. Start there, because the reason determines your response.

A plan-wide exclusion means the plan pays for no anti-obesity medication at all. It is a cost decision applied to every member. A step therapy denial means the insurer wants you to try other drugs first, often medications such as Contrave, Saxenda, or phentermine. Failure can include side effects you could not tolerate or a medical reason you could not take the required drug.

Other letters say Wegovy is not medically necessary, is not on the formulary, or did not meet prior authorization criteria. These can reflect missing documentation, formulary rules, or prior-authorization criteria, so the appeal should address the specific reason stated in the denial rather than assume the same explanation applies to every case.

Why Wegovy’s Label Matters

Wegovy was approved for chronic weight management in 2021. Since then, the FDA has added indications that can affect how a coverage request is evaluated.

In 2024, Wegovy was approved to reduce the risk of heart attack, stroke, and cardiovascular death in adults with established cardiovascular disease and obesity or overweight. The SELECT trial behind that approval enrolled more than 17,600 people and showed a 20% reduction in major cardiovascular events.

In 2025, the FDA approved Wegovy injection for adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis, classified as F2-F3, under accelerated approval. An oral Wegovy tablet was later approved for adult weight management and cardiovascular risk reduction, while the 7.2 mg Wegovy HD injection was approved for adult weight management. Coverage criteria can differ by formulation and indication.

A plan that excludes drugs when used solely for weight management may apply different criteria when Wegovy is prescribed for another FDA-approved indication. If you have established cardiovascular disease and overweight or obesity, or noncirrhotic MASH with F2-F3 fibrosis, ask your prescriber how the request should be documented. A step-therapy exception may also be worth asking about when the required alternatives do not address the FDA-approved indication at issue, but approval depends on the plan’s rules.

Three Ways to Challenge the Decision

These options may be used separately or as parts of the same appeal process, depending on your plan.

1. A Professional Appeal Service

The most hands-off route is to have specialists build and submit the appeal for you. Services such as Claimable and others prepare the full package, matching clinical evidence and policy analysis to your insurer and combining them with your personal account. Their experience across a large volume of GLP-1 appeals informs which arguments they lead with and when they escalate.

Outside help may make the most sense when the case is complicated: a blanket exclusion that calls for an alternate-indication argument, a step therapy dispute, or an appeal that has already been rejected once. It can also be a reasonable choice if you simply do not have the time to assemble everything yourself.

2. A Provider Appeal

Your prescriber can ask the insurer to reconsider by submitting a letter of medical necessity. For Wegovy, a few details may be particularly important. The letter should include your BMI from before treatment started if that information is relevant to the plan’s eligibility criteria, because a lower current weight may not reflect the circumstances under which treatment began.

It should also list relevant health conditions, including established cardiovascular disease, MASH, sleep apnea, prediabetes, or other conditions that may affect the coverage determination. If you are already doing well on Wegovy, the prescriber may also explain why continuity of care matters.

The letter can explain why Wegovy was chosen over alternatives, cite evidence relevant to the indication, such as STEP for weight management, SELECT for cardiovascular risk, or ESSENCE for MASH, and respond directly to the criteria listed by the insurer.

Practices vary in how often they write these letters, so ask plainly and offer to provide the criteria listed in your denial. Depending on the plan and type of denial, your doctor may also be able to request a peer-to-peer review with the insurer’s medical reviewer.

3. A Patient Appeal

If a provider request or prior authorization has been denied, check the denial notice to see whether you can file an internal appeal yourself or authorize your doctor or another representative to do so on your behalf. If the internal appeal is unsuccessful, plans subject to applicable federal or state protections may allow an independent external review. The number of review levels and applicable deadlines depends on the plan.

Your appeal should show how your case fits the plan’s own coverage rules, support that argument with relevant medical records, laboratory results, and published evidence, and include a concise explanation of what the denial means for your health and treatment.

Keep a record of when and how you submitted the appeal, along with confirmation numbers and the names of anyone you speak with. Maintaining a paper trail can help if documents need to be located or resubmitted.

If you have employer-sponsored coverage, a conversation with HR or your benefits department may also be worthwhile. Some employers exclude weight-management medications from their benefit design, and those decisions may be reconsidered as new indications and evidence emerge.

If CVS Caremark manages your pharmacy benefits, remember that its template formulary is not necessarily the same as your employer’s actual coverage. CVS made Wegovy preferred in 2025 and added Zepbound as another preferred option effective October 1, 2026, but plan sponsors can customize or exclude weight-management coverage. Check your specific plan before assuming the PBM’s standard formulary controls your benefit.

After You File

For plans subject to federal ACA appeal rules, an internal appeal involving care you have not yet received generally must be decided within 30 days; appeals involving services already received within 60 days; and urgent-care appeals within 72 hours.

If the internal appeal is unsuccessful and your plan qualifies for external review, standard external reviews must generally be decided no later than 45 days, while expedited external reviews must generally be decided no later than 72 hours. State rules and some employer plans may differ, so follow the process described in your denial notice.

Depending on your type of coverage, additional options may include contacting your state Department of Insurance or, for certain employer-sponsored plans governed by ERISA, pursuing the remedies available under that plan and federal law.

Check your denial letter for the filing deadline before anything else. Under federal ACA internal-appeal rules, consumers generally have 180 days from receiving the denial notice to file an appeal, although other coverage arrangements may follow different procedures.

A complete submission filed before the applicable deadline gives the reviewer the records and medical reasoning needed to evaluate the request.